What Tanabe Pharma America does

Tanabe Pharma America, Inc. is a U.S.-based pharmaceutical company and wholly-owned subsidiary of Tanabe Pharma Corporation (Japan, founded 1678). Established in 2016 and headquartered in Jersey City, New Jersey, the company develops and commercializes treatments for difficult-to-treat diseases, with historical focus on amyotrophic lateral sclerosis (ALS), Parkinson's disease, rare porphyrias, and more recently oncology. Its core technology centers on small-molecule pharmaceuticals for neurodegenerative and rare conditions, anchored by edaravone (marketed as RADICAVA/RADICAVA ORS), a free radical scavenger approved by FDA in 2017 as the first new ALS treatment in over 20 years, and a late-stage pipeline including dersimelagon (MT-7117, an oral MC1R agonist for EPP/XLP with positive Phase 3 INSPIRE results), ND0612 (continuous subcutaneous carbidopa/levodopa infusion for Parkinson's disease with FDA-accepted NDA resubmission), and MT-4561 (oncology candidate with first patient dosed June 2025).

The company generated revenue primarily through pharmaceutical product sales of RADICAVA ORS via specialty pharmacy distribution to over 22,000 ALS patients and 2,800 prescribing healthcare providers in the U.S., with additional royalty and licensing streams related to its edaravone portfolio. Its go-to-market model combines enterprise field sales directed at neurologists, ALS specialists, and infusion centers with event-driven medical affairs engagement at major neurology, dermatology, and rare disease conferences (MDA, AAN, ENCALS, AAD). Pricing is not publicly disclosed but operates on standard specialty pharmaceutical reimbursement pathways. In April 2026, TPA completed the $2.5 billion divestiture of its RADICAVA business to Shionogi Inc., transferring intellectual property, marketing rights, and over 100 team members, and is now positioned as a pipeline-focused organization preparing for potential launches of dersimelagon and ND0612.

Name

Tanabe Pharma America

Legal name

Tanabe Pharma America, Inc.

Website

https://us.tanabe-pharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Tanabe Pharma America is a U.S. pharmaceutical subsidiary of Tanabe Pharma Corporation developing treatments for difficult-to-treat diseases including ALS, Parkinson's disease, and rare porphyrias. Following the April 2026 $2.5 billion divestiture of RADICAVA to Shionogi, it is repositioning as a late-stage pipeline company.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• ALS treatment drugs
• Neurodegenerative pharmaceuticals
• Specialty pharmacy products
• Small molecule drug development

Headquarters

HQ city

Jersey City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: TPA generates revenue through commercialization of FDA-approved prescription pharmaceutical products in the United States. Revenue is derived from direct product sales and distribution through specialty pharmacies for treatments like RADICAVA ORS.
2. Royalty Repurchase: Following the $2.5B RADICAVA sale to Shionogi, Mineralys Therapeutics repurchased the royalty obligation under its license agreement with Tanabe Pharma Corporation for $750 million (with $200M upfront payment and $500M debt facility).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Tanabe Pharma America develops and commercializes prescription pharmaceutical products for serious, difficult-to-treat diseases in North America. Its approved product RADICAVA (edaravone) treats amyotrophic lateral sclerosis (ALS), with global rights transferred to Shionogi in April 2026. The company is now focused on advancing a late-stage pipeline of investigational therapies, including dersimelagon for erythropoietic protoporphyria (EPP/XLP), ND0612 for Parkinson's disease, and MT-4561 for advanced solid tumors.

Product overview

Tanabe Pharma America is a wholly-owned subsidiary of Tanabe Pharma Corporation focused on developing and commercializing pharmaceutical treatments for serious and debilitating diseases. The company operates a late-stage pipeline of investigational treatments and previously commercialized RADICAVA (edaravone) for ALS. Product portfolio includes: RADICAVA/RADICAVA ORS (FDA-approved ALS treatment, rights transferred to Shionogi April 2026); pipeline candidates including dersimelagon (MT-7117) for EPP/XLP (Phase 3 completed), ND0612 for Parkinson's disease motor fluctuations (NDA accepted), MT-4561 for oncology; and discontinued products EXSERVAN and IV RADICAVA. The company focuses on central nervous system, immuno-inflammation, diabetes and kidney, and cancer therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• RADICAVA ORS (edaravone oral suspension) FDA-approved oral suspension formulation of edaravone for the treatment of amyotrophic lateral sclerosis (ALS). A free radical scavenger that mitigates oxidative stress to slow physical decline in ALS patients. Dispensed through specialty pharmacies for healthcare providers treating ALS patients.
• Dersimelagon (MT-7117) Investigational novel synthetic, orally-administered, non-peptide small molecule that acts as a selective agonist of the melanocortin-1 receptor (MC1R) for the treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP). Phase 3 INSPIRE study completed with positive results.
• ND0612 Investigational continuous subcutaneous carbidopa/levodopa infusion therapy for Parkinson's disease patients experiencing motor fluctuations. Delivered via pump system for continuous 24-hour dosing. Phase 3 BouNDless trial completed with positive results; NDA resubmission accepted by FDA.
• MT-4561 Investigational oncology asset for the treatment of advanced solid tumors. First patient dosed in clinical trial in June 2025.

Quantifiable outcome

• Over 22,000 ALS patients treated with RADICAVA therapies in the U.S.
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• GHIT Fund (Global Health Innovative Technology Fund)minorStrategic or Co-development Partner · 22 April 2026GHIT Fund announced approximately USD 8.5 million investment in malaria and NTD R&D projects, including JPY 700 million (USD 4.4 million) for preclinical development of antimalarial drug MMV172 involving MMV, Tanabe Pharma, and University of Georgia.
• Shionogi & Co., Ltd.coreTechnology or Integration · 1 April 2026Transfer of RADICAVA (edaravone) business to Shionogi for $2.5 billion completed April 2026. Shionogi acquired global rights including IP and marketing rights. Over 100 TPA team members joined Shionogi as part of the integration.
• Dewpoint TherapeuticscoreStrategic or Co-development Partner · 17 December 2024Research collaboration between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to advance small molecule condensate modulator for ALS. This partnership leverages Dewpoint's condensate biology platform to develop novel therapeutics targeting ALS.
• Nobias TherapeuticsminorStrategic or Co-development Partner · 4 September 2024Completion of AI collaboration to further understanding of Autism Spectrum Disorder. The partnership explored applications of AI and machine learning in autism research.
• Massachusetts General HospitalminorStrategic or Co-development PartnerCollaboration with Massachusetts General Hospital on ALS biomarker study for real-world data collection in ALS to improve patient care.
• ALS/MND Natural History Study ConsortiumminorStrategic or Co-development PartnerPartnership to collect real-world data in ALS with the goal of improving patient care through natural history documentation.
• Oxford BiodynamicsminorStrategic or Co-development PartnerCollaboration on ALS biomarker study; Oxford Biodynamics joined the REFINE-ALS biomarker study sponsored by TPA.
• Neuroderm Ltd.coreTechnology or IntegrationPartnership for ND0612 development - continuous subcutaneous carbidopa/levodopa infusion for Parkinson's disease. Neuroderm developed the formulation technology that was incorporated into the product.
• Maze TherapeuticscoreTechnology or IntegrationShionogi acquired exclusive worldwide rights to S-606001 (substrate reduction therapy for Pompe disease) from Maze Therapeutics in 2024. S-606001 received rare pediatric disease designation from FDA in 2025.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Lundbeck: Established CNS specialty pharmaceutical company with broad neurology and rare-disease portfolio. Comparable on CNS specialty pharma commercial model and difficult-to-treat CNS focus.
• AbbVie: Markets Duopa (carbidopa/levodopa intestinal gel infusion), the established continuous-levodopa Parkinson's therapy that ND0612 would compete against. Large incumbent with deep neurology commercial reach.
• Biogen: Large established neurology and rare-disease player with ALS assets (including Tofersen/Qalsody) and a broad specialty neurology portfolio. Overlaps with TPA on CNS focus and rare-disease commercialization.

Direct peers

• Disc Medicine: Direct competitor in EPP/XLP with bitopertin (a different mechanism for erythropoietic protoporphyria). Most comparable peer to dersimelagon's indication and ultra-rare hematology/dermatology positioning.
• Amylyx Pharmaceuticals: Direct ALS competitor with Relyvrio (AMX0035), the most recent FDA-approved ALS therapy. Compares to TPA on ALS indication, specialty neurology distribution, and difficult-to-treat neurodegenerative disease focus.
• Alnylam Pharmaceuticals: RNAi-based rare disease therapeutics company with porphyria franchise (Givlaari for AHP). Comparable on rare-disease R&D, ultra-orphan launch execution, and heme-pathway disorders overlapping with EPP/XLP.
• Acadia Pharmaceuticals: CNS specialty pharma focused on rare disorders (e.g., Rett syndrome with Daybue). Comparable specialty-neurology commercial model targeting difficult-to-treat CNS conditions.
• Ionis Pharmaceuticals: Antisense-based rare neurology biotech with multiple ALS, SMA, and CNS programs. Comparable on rare neurology pipeline development and late-stage neurodegenerative disease focus.
• Clene Nanomedicine: ALS-focused clinical-stage biotech developing CNM-Au8, a gold nanocatalyst for neurodegenerative disease. Direct peer on ALS pipeline development and difficult-to-treat neurology positioning.

Others

• Mitsubishi Tanabe Pharma Corporation: Parent company of TPA and originator of edaravone/dersimelagon/ND0612 development programs. Listed as OTHERS due to direct corporate relationship, but comparable on therapeutic area, pipeline assets, and Japan-U.S. pharma model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mtpa_us
• YouTubeyoutube.com/@TanabePharmaUS
• Facebookfacebook.com/TanabePharmaAmerica
• LinkedInlinkedin.com/company/mitsubishi-tanabe-pharma-america

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tanabe Pharma America